CompletedNCT01940978
A Study of Combination Therapy in Children With ADHD
Medication studyAges 6–12United States
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
- Listed locations
- Van NuysSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMarch 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 99
- Sponsor
- Douglas Sears
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT01940978
- Official title
Show the full official title
A Double-Blind Placebo-Controlled Study of Combination Therapy in Children With ADHD
Recruitment & locations
CompletedVan Nuys
Questions about this study
Who is behind this study?
The study sponsor is Douglas Sears.
Did this study involve medication?
Yes. The study involved medication, including Methylphenidate ER and Cyproheptadine.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)